Резюме: Буздин Антон Александрович

Адрес

Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук, Москва, Россия

Контакты

https://www.ibch.ru/ru/users/9

Работа в ИБХ

2015–наст.вр.	Ведущий научный сотрудник

Награды

2016	Премия Правительства Москвы молодым ученым	За цикл работ по созданию системы широкомасштабного анализа генной экспрессии «OncoFinder»
2003	Медали РАН для молодых ученых и студентов с премией	За работу «Полногеномная идентификация мобильных элементов, специфичных для ДНК человека»

Членство в сообществах

с 2002 — Член Европейского биохимического сообщества (FEBS).
с 2006 — Член Американского общества микробиологов (American Society for Microbiology).
с 2005 — Член Российского общества охраны птиц.

Степени и звания

Доктор наук (Биологические науки, 03.00.03 — Молекулярная биология)

Гранты и проекты

2018–2022	Выявление факторов, препятствующих успешной HER-таргетной терапии при раке молочной железы и разработка противоопухолевого препарата, связывающего HER-лиганды

Публикации

1. Mohammad T, Zolotovskaia MA, Suntsova MV, **Buzdin AA** (2024). Cancer fusion transcripts with human non-coding RNAs. *Front Oncol* 14, 1415801, 10.3389/fonc.2024.1415801
2. Rakhimbekova F, Kaidarova DR, Orazgalieva M, Ryspambetov Z, **Buzdin A**, Anapiyayev B (2024). Cancer Incidence Relation to Heavy Metals in Soils of Kyzylorda Region of Kazakhstan. *Asian Pac J Cancer Prev* 25 (6), 1987–1995, 10.31557/APJCP.2024.25.6.1987
3. Drobyshev A, Modestov A, Suntsova M, Poddubskaya E, Seryakov A, Moisseev A, Sorokin M, Tkachev V, Zakharova G, Simonov A, Zolotovskaia MA, **Buzdin A** (2024). Pan-cancer experimental characteristic of human transcriptional patterns connected with telomerase reverse transcriptase () gene expression status. *Front Genet* 15, 1401100, 10.3389/fgene.2024.1401100
4. Li X, Wang Y, Yang J, **Buzdin A** (2024). Editorial: Application of multi-omics technologies to explore novel biological process and molecular function in immunology and oncology. *Front Genet* 15, 1403796, 10.3389/fgene.2024.1403796
5. Raevskiy M, Sorokin M, Emelianova A, Zakharova G, Poddubskaya E, Zolotovskaia M, **Buzdin A** (2024). Sample-Wise and Gene-Wise Comparisons Confirm a Greater Similarity of RNA and Protein Expression Data at the Level of Molecular Pathways and Suggest an Approach for the Data Quality Check in High-Throughput Expression Databases. *Biochemistry (Mosc)* 89 (4), 737–746, 10.1134/S0006297924040126

6. Khilal NR, Suntsova MV, Knyazev DI, Guryanova AA, Kovaleva TF, Sorokin MI, **Buzdin AA**, Katkova NY (2024). Adaptation and Experimental Validation of Clinical RNA Sequencing Protocol Oncobox for MGI DNBSEQ-G50 Platform. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry* 17 (4), 172–182, 10.1134/S1990750823600589

7. Shaban N, Raevskiy M, Zakharova G, Shipunova V, Deyev S, Suntsova M, Sorokin M, **Buzdin A**, Kamashev D (2024). Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression. *Biochemistry (Mosc)* 89 (3), 487–506, 10.1134/S000629792403009X

8. Shaban N, Kamashev D, Emelianova A, **Buzdin A** (2023). Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. *Cells* 13 (1), , 10.3390/cells13010047

9. Salvati A, Ferravante C, Lamberti J, Rocco T, Alexandrova E, DAgostino Y, Sorokin M, Efimov V, **Buzdin A**, Strianese O, Nassa G, Tarallo R, Weisz A, Rizzo F, Giurato G (2023). Erratum: Author Correction: Host nasopharyngeal transcriptome dataset of a SARS-CoV-2 positive Italian cohort (Scientific data (2023) 10 1 (379)). *Sci Data* 10 (1), 588, 10.1038/s41597-023-02504-5

10. Borisov N, Tkachev V, Simonov A, Sorokin M, Kim E, Kuzmin D, Karademir-Yilmaz B, **Buzdin A** (2023). Uniformly shaped harmonization combines human transcriptomic data from different platforms while retaining their biological properties and differential gene expression patterns. *Front Mol Biosci* 10, 1237129, 10.3389/fmolb.2023.1237129

11. Zolotovskaia M, Kovalenko M, Pugacheva P, Tkachev V, Simonov A, Sorokin M, Seryakov A, Garazha A, Gaifullin N, Sekacheva M, Zakharova G, **Buzdin AA** (2023). Algorithmically Reconstructed Molecular Pathways as the New Generation of Prognostic Molecular Biomarkers in Human Solid Cancers. *Proteomes* 11 (3), , 10.3390/proteomes11030026

12. Kamashev D, Shaban N, Lebedev T, Prassolov V, Suntsova M, Raevskiy M, Gaifullin N, Sekacheva M, Garazha A, Poddubskaya E, Sorokin M, **Buzdin A** (2023). Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways. *Cells* 12 (16), , 10.3390/cells12162022

13. Sorokin MI, **Buzdin AA**, Guryanova A, Efimov V, Suntsova MV, Zolotovskaia MA, Koroleva EV, Sekacheva MI, Tkachev VS, Garazha A, Kremenchutckaya K, Drobyshev A, Seryakov A, Gudkov A, Alekseenko IV, Rakitina OA, Kostina MB, Vladimirova U, Moisseev A, Bulgin D, Radomskaya E, Shestakov V, Baklaushev VP, Prassolov V, Shegay PV, Li X, Poddubskaya EV, Gaifullin N (2023). Large-scale assessment of pros and cons of autopsy-derived or tumor-matched tissues as the norms for gene expression analysis in cancers. *Comput Struct Biotechnol J* 21, 3964–3986, 10.1016/j.csbj.2023.07.040

14. Wang Y, Liu B, Zhao G, Lee Y, **Buzdin A**, Mu X, Zhao J, Chen H, Li X (2023). Spatial transcriptomics: Technologies, applications and experimental considerations. *Genomics* 115 (5), 110671, 10.1016/j.ygeno.2023.110671

15. Salvati A, Ferravante C, Lamberti J, Rocco T, Alexandrova E, DAgostino Y, Sorokin M, Efimov V, **Buzdin A**, Strianese O, Nassa G, Tarallo R, Weisz A, Rizzo F, Giurato G (2023). Host nasopharyngeal transcriptome dataset of a SARS-CoV-2 positive Italian cohort. *Sci Data* 10 (1), 379, 10.1038/s41597-023-02289-7

16. Zakharova G, Modestov A, Pugacheva P, Mekic R, Savina E, Guryanova A, Rachkova A, Yakushov S, Alimov A, Kulaeva E, Fedoseeva E, Kleyman A, Vasin K, Tkachev V, Garazha A, Sekacheva M, Suntsova M, Sorokin M, **Buzdin A**, Zolotovskaia MA (2023). Distinct Traits of Structural and Regulatory Evolutional Conservation of Human Genes with Specific Focus on Major Cancer Molecular Pathways. *Cells* 12 (9), , 10.3390/cells12091299

17. Rozenberg JM, **Buzdin AA**, Mohammad T, Rakitina OA, Didych DA, Pleshkan VV, Alekseenko IV (2023). Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers. *Front Immunol* 14, 1099921, 10.3389/fimmu.2023.1099921

18. Zolotovskaia MA, Modestov AA, Suntsova MV, Rachkova AA, Koroleva EV, Poddubskaya EV, Sekacheva MI, Tkachev VS, Garazha AV, Glusker AA, Seryakov AP, Vladimirova US, Rumiantsev PO, Moisseev AA, Zharkov DO, Kuzmin DV, Zhao X, Prassolov VS, Shegay PV, Li X, Steinbichler TB, Kim E, Sorokin MI, Wang Y, **Buzdin AA** (2023). Pan-cancer antagonistic inhibition pattern of ATM-driven G2/M checkpoint pathway vs other DNA repair pathways. *DNA Repair (Amst)* 123, 103448, 10.1016/j.dnarep.2023.103448

19. Pustovalova M, Malakhov P, Guryanova A, Sorokin M, Suntsova M, **Buzdin A**, Osipov AN, Leonov S (2023).

Transcriptome-Based Traits of Radioresistant Sublines of Non-Small Cell Lung Cancer Cells. *Int J Mol Sci* 24 (3), 3042, 10.3390/ijms24033042

20. Zakharova G, Efimov V, Raevskiy M, Rumiantsev P, Gudkov A, Belogurova-Ovchinnikova O, Sorokin M, **Buzdin A** (2023). Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification. *Int J Mol Sci* 24 (1), 157, 10.3390/ijms24010157

21. Kalmykova A, **Buzdin A** (2023). Evolution of Epigenetic Mechanisms and Signatures. *Cells* 12 (1), , 10.3390/cells12010109

22. Sorokin M, Rabushko E, Rozenberg JM, Mohammad T, Seryakov A, Sekacheva M, **Buzdin A** (2022). Clinically relevant fusion oncogenes: detection and practical implications. *Ther Adv Med Oncol* 14, 17588359221144108, [10.1177/17588359221144108](10.1177/17588359221144108)

23. Sorokin M, Zolotovskaia M, Nikitin D, Suntsova M, Poddubskaya E, Glusker A, Garazha A, Moisseev A, Li X, Sekacheva M, Naskhletashvili D, Seryakov A, Wang Y, **Buzdin A** (2022). Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data. *BMC Cancer* 22 (1), 1113, [10.1186/s12885-022-10177-3](10.1186/s12885-022-10177-3)

24. Borisov N, **Buzdin A** (2022). Transcriptomic Harmonization as the Way for Suppressing Cross-Platform Bias and Batch Effect. *Biomedicines* 10 (9), , 10.3390/biomedicines10092318

25. Kamashev D, Shaban N, Suntsova M, Raevskiy M, Efimov V, Moisseev A, Sorokin M, **Buzdin A** (2022). Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. *Biomedicines* 10 (8), , 10.3390/biomedicines10081914

26. Rabushko E, Sorokin M, Suntsova M, Seryakov AP, Kuzmin DV, Poddubskaya E, **Buzdin AA** (2022). Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3′ Oncogenes from FFPE Bulk RNA Sequencing Data. *Biomedicines* 10 (8), , 10.3390/biomedicines10081866

27. Lebedev T, **Buzdin A**, Khabusheva E, Spirin P, Suntsova M, Sorokin M, Popenko V, Rubtsov P, Prassolov V (2022). Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling. *Int J Mol Sci* 23 (14), , 10.3390/ijms23147724

28. Lebedev TD, Khabusheva ER, Mareeva SR, Ivanenko KA, Morozov AV, Spirin PV, Rubtsov PM, Snezhkina AV, Kudryavtseva AV, Sorokin MI, **Buzdin AA**, Prassolov VS (2022). Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. *J Biol Chem* 298 (8), 102226, [10.1016/j.jbc.2022.102226](10.1016/j.jbc.2022.102226)

29. Zolotovskaia MA, Kovalenko MA, Tkachev VS, Simonov AM, Sorokin MI, Kim E, Kuzmin DV, Karademir-Yilmaz B, **Buzdin AA** (2022). Next-Generation Grade and Survival Expression Biomarkers of Human Gliomas Based on Algorithmically Reconstructed Molecular Pathways. *Int J Mol Sci* 23 (13), , 10.3390/ijms23137330

30. Zolotovskaia MA, Tkachev VS, Guryanova AA, Simonov AM, Raevskiy MM, Efimov VV, Wang Y, Sekacheva MI, Garazha AV, Borisov NM, Kuzmin DV, Sorokin MI, **Buzdin AA** (2022). OncoboxPD: human 51 672 molecular pathways database with tools for activity calculating and visualization. *Comput Struct Biotechnol J* 20, 2280–2291, 10.1016/j.csbj.2022.05.006

31. Rozenberg JM, Kamynina M, Sorokin M, Zolotovskaia M, Koroleva E, Kremenchutckaya K, Gudkov A, **Buzdin A**, Borisov N (2022). The Role of the Metabolism of Zinc and Manganese Ions in Human Cancerogenesis. *Biomedicines* 10 (5), , 10.3390/biomedicines10051072

32. Borisov N, Sorokin M, Zolotovskaya M, Borisov C, **Buzdin A** (2022). Shambhala-2: A Protocol for Uniformly Shaped Harmonization of Gene Expression Profiles of Various Formats. *Curr. prot.* 2 (5), e444, [10.1002/cpz1.444](10.1002/cpz1.444)

33. Konovalov N, Timonin S, Asyutin D, Raevskiy M, Sorokin M, **Buzdin A**, Kaprovoy S (2022). Transcriptomic Portraits and Molecular Pathway Activation Features of Adult Spinal Intramedullary Astrocytomas. *Front Oncol* 12, 837570, 10.3389/fonc.2022.837570

34. Gudkov A, Shirokorad V, Kashintsev K, Sokov D, Nikitin D, Anisenko A, Borisov N, Sekacheva M, Gaifullin N, Garazha A, Suntsova M, Koroleva E, **Buzdin A**, Sorokin M (2022). Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer. *Front Mol Biosci* 9, 753318, 10.3389/fmolb.2022.753318

35. Raevskiy M, Sorokin M, Zakharova G, Tkachev V, Borisov N, Kuzmin D, Kremenchutckaya K, Gudkov A, Kamashev D, **Buzdin A** (2022). Better Agreement of Human Transcriptomic and Proteomic Cancer Expression Data at the Molecular Pathway Activation Level. *Int J Mol Sci* 23 (5), , 10.3390/ijms23052611

36. Moiseev AA, Guriyanova AA, Suntsova MV, **Buzdin AA**, Sorokin MI (2022). A case of whole-exome and transcriptome sequencing of tumor for personalized experimental treatment for metastatic mesothelioma. *Herzen Oncology* 11 (2), 62–67, 10.17116/onkolog20221102162

37. Sorokin M, Rabushko E, Efimov V, Poddubskaya E, Sekacheva M, Simonov A, Nikitin D, Drobyshev A, Suntsova M, **Buzdin A** (2021). Experimental and Meta-Analytic Validation of RNA Sequencing Signatures for Predicting Status of Microsatellite Instability. *Front Mol Biosci* 8, 737821, 10.3389/fmolb.2021.737821

38. Schneider MA, **Buzdin AA**, Weber A, Clavien PA, Borger P (2021). Combination of antiretroviral drugs zidovudine and efavirenz impairs tumor growths in a mouse model of cancer. *Viruses* 13 (12), , 10.3390/v13122396

39. Raevskiy M, Sorokin M, Vladimirova U, Suntsova M, Efimov V, Garazha A, Drobyshev A, Moisseev A, Rumiantsev P, Li X, **Buzdin A** (2021). EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers. *Biochemistry (Mosc)* 86 (11), 1477–1488, 10.1134/S0006297921110110

40. Sorokin M, Gorelyshev A, Efimov V, Zotova E, Zolotovskaia M, Rabushko E, Kuzmin D, Seryakov A, Kamashev D, Li X, Poddubskaya E, Suntsova M, **Buzdin A** (2021). RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples. *Front Oncol* 11, 732644, 10.3389/fonc.2021.732644

41. Lebedev T, Vagapova E, Spirin P, Rubtsov P, Astashkova O, Mikheeva A, Sorokin M, Vladimirova U, Suntsova M, Konovalov D, Roumiantsev A, Stocking C, **Buzdin A**, Prassolov V (2021). Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes. *Oncogene* 40 (44), 6258–6272, 10.1038/s41388-021-02018-7

42. Seryakov A, Magomedova Z, Suntsova M, Prokofieva A, Rabushko E, Glusker A, Makovskaia L, Zolotovskaia M, **Buzdin A**, Sorokin M (2021). RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report. *Front Oncol* 11, 666001, 10.3389/fonc.2021.666001

43. Zolotovskaia M, Tkachev V, Sorokin M, Garazha A, Kim E, Kantelhardt SR, Bikar SE, Zottel A, Šamec N, Kuzmin D, Sprang B, Moisseev A, Giese A, Efimov V, Jovčevska I, **Buzdin A** (2021). Algorithmically deduced FREM2 molecular pathway is a potent grade and survival biomarker of human gliomas. *Cancers (Basel)* 13 (16), , 10.3390/cancers13164117

44. Samii A, Sorokin M, Kar S, Makovskaia L, Garazha A, Hartmann C, Moisseev A, Kim E, Giese A, **Buzdin A** (2021). Case of multifocal glioblastoma with four fusion transcripts of ALK, FGFR2, NTRK2, and NTRK3 genes stresses the need for tumor tissue multisampling for transcriptomic analysis. *Cold Spring Harb Mol Case Stud* 7 (4), , 10.1101/mcs.a006100

45. **Buzdin AV**, Patrushev MV, Sverdlov ED (2021). Will plant genome editing play a decisive role in "quantum-leap" improvements in crop yield to feed an increasing global human population? *Plants (Basel)* 10 (8), , 10.3390/plants10081667

46. Sorokin M, Raevskiy M, Zottel A, Šamec N, Skoblar Vidmar M, Matjašič A, Zupan A, Mlakar J, Suntsova M, Kuzmin DV, **Buzdin A**, Jovčevska I (2021). Large-Scale Transcriptomics-Driven Approach Revealed Overexpression of CRNDE as a Poor Survival Prognosis Biomarker in Glioblastoma. *Cancers (Basel)* 13 (14), , 10.3390/cancers13143419

47. Wang Y, Tong Z, Zhang W, Zhang W, **Buzdin A**, Mu X, Yan Q, Zhao X, Chang HH, Duhon M, Zhou X, Zhao G, Chen H, Li X (2021). FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. *Front Oncol* 11, 683419, 10.3389/fonc.2021.683419

48. Aschenbrenner B, Negro G, Savic D, Sorokin M, **Buzdin A**, Ganswindt U, Cemazar M, Sersa G, Skvortsov S, Skvortsova I (2021). Simvastatin is effective in killing the radioresistant breast carcinoma cells. *Radiol Oncol* 55 (3), 305–316, 10.2478/raon-2021-0020

49. Borisov N, Sergeeva A, Suntsova M, Raevskiy M, Gaifullin N, Mendeleeva L, Gudkov A, Nareiko M, Garazha A, Tkachev V, Li X, Sorokin M, Surin V, **Buzdin A** (2021). Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles. *Front Oncol* 11, 652063, 10.3389/fonc.2021.652063

50. **Buzdin A**, Tkachev V, Zolotovskaia M, Garazha A, Moshkovskii S, Borisov N, Gaifullin N, Sorokin M, Suntsova M (2021). Chapter One - Using proteomic and transcriptomic data to assess activation of intracellular molecular pathways. *Adv Protein Chem Struct Biol* 127, 1–53, 10.1016/bs.apcsb.2021.02.005

51. Vladimirova U, Rumiantsev P, Zolotovskaia M, Albert E, Abrosimov A, Slashchuk K, Nikiforovich P, Chukhacheva O, Gaifullin N, Suntsova M, Zakharova G, Glusker A, Nikitin D, Garazha A, Li X, Kamashev D, Drobyshev A, Kochergina-Nikitskaya I, Sorokin M, **Buzdin A** (2021). DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles. *Heliyon* 7 (3), e06408, 10.1016/j.heliyon.2021.e06408

52. Kamashev D, Sorokin M, Kochergina I, Drobyshev A, Vladimirova U, Zolotovskaia M, Vorotnikov I, Shaban N, Raevskiy M, Kuzmin D, **Buzdin A** (2021). Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth. *Heliyon* 7 (3), e06394, 10.1016/j.heliyon.2021.e06394

53. Sorokin M, Borisov N, Kuzmin D, Gudkov A, Zolotovskaia M, Garazha A, **Buzdin A** (2021). Algorithmic Annotation of Functional Roles for Components of 3,044 Human Molecular Pathways. *Front Genet* 12, 617059, 10.3389/fgene.2021.617059

54. **Buzdin A**, Skvortsova II, Li X, Wang Y (2021). Editorial: Next Generation Sequencing Based Diagnostic Approaches in Clinical Oncology. *Front Oncol* 10, 635555, 10.3389/fonc.2020.635555

55. Blinova E, **Buzdin A**, Enikeev D, Roshchin D, Suntsova M, Samyshina E, Drobyshev A, Deryabina O, Demura T, Blinov D, Shich E, Barakat H, Borger P, Merinov D, Kachmazov A, Serebrianyi S, Tumutolova O, Potoldykova N, Zhdanov P, Grigoryan V, Perepechin D (2020). Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma. *Life (Basel)* 10 (11), 1–14, 10.3390/life10110305

56. Zottel A, Šamec N, Kump A, Raspor DallOlio LR, Pužar Dominkuš P, Romih R, Hudoklin S, Mlakar J, Nikitin D, Sorokin M, **Buzdin A**, Jovčevska I, Komel R (2020). Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles. *Int J Mol Sci* 21 (22), 1–22, 10.3390/ijms21228491

57. Borisov N, Sorokin M, Tkachev V, Garazha A, **Buzdin A** (2020). Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments. *BMC Med Genomics* 13 (Suppl 8), 111, 10.1186/s12920-020-00759-0

58. Suntsova MV, **Buzdin AA** (2020). Differences between human and chimpanzee genomes and their implications in gene expression, protein functions and biochemical properties of the two species. *BMC Genomics* 21 (Suppl 7), 535, 10.1186/s12864-020-06962-8

59. Knyazeva M, Korobkina E, Karizky A, Sorokin M, **Buzdin A**, Vorobyev S, Malek A (2020). Reciprocal Dysregulation of MiR-146b and MiR-451 Contributes in Malignant Phenotype of Follicular Thyroid Tumor. *Int J Mol Sci* 21 (17), 1–17, 10.3390/ijms21175950

60. Sorokin M, Ignatev K, Barbara V, Vladimirova U, Muraveva A, Suntsova M, Gaifullin N, Vorotnikov I, Kamashev D, Bondarenko A, Baranova M, Poddubskaya E, **Buzdin A** (2020). Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels. *Biochemistry (Mosc)* 85 (7), 758–772, 10.1134/S0006297920070044

61. Sorokin M, Kholodenko I, Kalinovsky D, Shamanskaya T, Doronin I, Konovalov D, Mironov A, Kuzmin D, Nikitin D, Deyev S, **Buzdin A**, Kholodenko R (2020). RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype. *Biomedicines* 8 (6), , 10.3390/biomedicines8060142

62. Sorokin M, Ignatev K, Poddubskaya E, Vladimirova U, Gaifullin N, Lantsov D, Garazha A, Allina D, Suntsova M, Barbara V, **Buzdin A** (2020). RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens. *Biomedicines* 8 (5), , 10.3390/biomedicines8050114

63. Borger P, **Buzdin A**, Sorokin M, Kachaylo E, Humar B, Graf R, Clavien PA (2020). Large-Scale Profiling of Signaling Pathways Reveals a Distinct Demarcation between Normal and Extended Liver Resection. *Cells* 9 (5), , 10.3390/cells9051149

64. Kalasauskas D, Sorokin M, Sprang B, Elmasri A, Viehweg S, Salinas G, Opitz L, Rave-Fraenk M, Schulz-Schaeffer W, Kantelhardt SR, Giese A, **Buzdin A**, Kim EL (2020). Diversity of Clinically Relevant Outcomes Resulting from Hypofractionated Radiation in Human Glioma Stem Cells Mirrors Distinct Patterns of Transcriptomic Changes. *Cancers (Basel)* 12 (3), , 10.3390/cancers12030570

65. Zolotovskaia MA, Sorokin MI, Petrov IV, Poddubskaya EV, Moiseev AA, Sekacheva MI, Borisov NM, Tkachev

VS, Garazha AV, Kaprin AD, Shegay PV, Giese A, Kim E, Roumiantsev SA, **Buzdin AA** (2020). Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. *Int J Mol Sci* 21 (5), 1–18, 10.3390/ijms21051580

66. Kim EL, Sorokin M, Kantelhardt SR, Kalasauskas D, Sprang B, Fauss J, Ringel F, Garazha A, Albert E, Gaifullin N, Hartmann C, Naumann N, Bikar SE, Giese A, **Buzdin A** (2020). Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma. *Cancers (Basel)* 12 (2), , 10.3390/cancers12020520

67. Negro G, Aschenbrenner B, Brezar SK, Cemazar M, Coer A, Gasljevic G, Savic D, Sorokin M, **Buzdin A**, Callari M, Kvitsaridze I, Jewett A, Vasileva-Slaveva M, Ganswindt U, Skvortsova I, Skvortsov S (2020). Molecular heterogeneity in breast carcinoma cells with increased invasive capacities. *Radiol Oncol* 54 (1), 103–118, 10.2478/raon-2020-0007

68. Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, Allina D, Suntsova M, Tkachev V, Garazha A, Sekacheva M, **Buzdin A** (2020). RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. *Cold Spring Harb Mol Case Stud* 6 (2), , 10.1101/mcs.a004945

69. Zolotovskaia MA, Tkachev VS, Seryakov AP, Kuzmin DV, Kamashev DE, Sorokin MI, Roumiantsev SA, **Buzdin AA** (2020). Mutation Enrichment and Transcriptomic Activation Signatures of 419 Molecular Pathways in Cancer. *Cancers (Basel)* 12 (2), , 10.3390/cancers12020271

70. Tkachev V, Sorokin M, Borisov C, Garazha A, **Buzdin A**, Borisov N (2020). Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology. *Int J Mol Sci* 21 (3), , 10.3390/ijms21030713

71. **(книга)** Tkachev V, Sorokin M, Garazha A, Borisov N, **Buzdin A** (2020). Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. *Methods Mol Biol* 2063, 235–255, 10.1007/978-1-0716-0138-9_17

72. **(книга)** Zolotovskaia M, Sorokin M, Garazha A, Borisov N, **Buzdin A** (2020). Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. *Methods Mol Biol* 2063, 207–234, 10.1007/978-1-0716-0138-9_16

73. **(книга)** Borisov N, Sorokin M, Garazha A, **Buzdin A** (2020). Quantitation of Molecular Pathway Activation Using RNA Sequencing Data. *Methods Mol Biol* 2063, 189–206, 10.1007/978-1-0716-0138-9_15

74. Borger P, Schneider M, Frick L, Langiewicz M, Sorokin M, **Buzdin A**, Kachaylo E, Graf R, Humar B, Clavien PA (2019). Exploration of the Transcriptional Landscape of ALPPS Reveals the Pathways of Accelerated Liver Regeneration. *Front Oncol* 9, 1206, 10.3389/fonc.2019.01206

75. Nikitin D, Kolosov N, Murzina A, Pats K, Zamyatin A, Tkachev V, Sorokin M, Kopylov P, **Buzdin A** (2019). Retroelement-Linked H3K4me1 Histone Tags Uncover Regulatory Evolution Trends of Gene Enhancers and Feature Quickly Evolving Molecular Processes in Human Physiology. *Cells* 8 (10), , 10.3390/cells8101219

76. **(книга)** Nikitin D, Sorokin M, Tkachev V, Garazha A, Markov A, **Buzdin A** (2019). RetroSpect, a new method of measuring gene regulatory evolution rates using co-mapping of genomic functional features with transposable elements. *Evolution, Origin of Life, Concepts and Methods* 42 (1), 85–111, 10.1007/978-3-030-30363-1_5

77. Igolkina AA, Zinkevich A, Karandasheva KO, Popov AA, Selifanova MV, Nikolaeva D, Tkachev V, Penzar D, Nikitin DM, **Buzdin A** (2019). H3K4me3, H3K9ac, H3K27ac, H3K27me3 and H3K9me3 Histone Tags Suggest Distinct Regulatory Evolution of Open and Condensed Chromatin Landmarks. *Cells* 8 (9), , 10.3390/cells8091034

78. **Buzdin A**, Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E, Sekacheva M, Kim E, Gaifullin N, Giese A, Seryakov A, Rumiantsev P, Moshkovskii S, Moiseev A (2019). RNA sequencing for research and diagnostics in clinical oncology. *Semin Cancer Biol* 60, 311–323, 10.1016/j.semcancer.2019.07.010

79. Nikitin D, Garazha A, Sorokin M, Penzar D, Tkachev V, Markov A, Gaifullin N, Borger P, Poltorak A, **Buzdin A** (2019). Correction: Nikitin, D., et al. Retroelement-Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution. 2019, , 130. *Cells* 8 (8), , 10.3390/cells8080832

80. Jovčevska I, Zottel A, Šamec N, Mlakar J, Sorokin M, Nikitin D, **Buzdin AA**, Komel R (2019). High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas. *Cancers (Basel)* 11 (8), , 10.3390/cancers11081060

81. Borisov N, **Buzdin A** (2019). New Paradigm of Machine Learning (ML) in Personalized Oncology: Data Trimming for Squeezing More Biomarkers From Clinical Datasets. *Front Oncol* 9, 658, 10.3389/fonc.2019.00658

82. **(конференция)** Доронин ИИ, **Буздин АА**, Сорокин МИ, Холоденко ИВ, Деев СМ, Холоденко РВ (2019). The approach for selection optimal combinations of chemotherapy drugs with GD2-specific antibodies for the effective elimination of GD2-positive tumor cells. *FEBS Open Bio* 9 (S1), 339, https://doi.org/10.1002/2211-5463.12675

83. Suntsova M, Gaifullin N, Allina D, Reshetun A, Li X, Mendeleeva L, Surin V, Sergeeva A, Spirin P, Prassolov V, Morgan A, Garazha A, Sorokin M, **Buzdin A** (2019). Atlas of RNA sequencing profiles for normal human tissues. *Sci Data* 6 (1), 36, 10.1038/s41597-019-0043-4

84. **Buzdin A**, Sorokin M, Poddubskaya E, Borisov N (2019). High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology. *Cancer Inform* 18, 1176935119838844, 10.1177/1176935119838844

85. Borisov N, Shabalina I, Tkachev V, Sorokin M, Garazha A, Pulin A, Eremin II, **Buzdin A** (2019). Shambhala: a platform-agnostic data harmonizer for gene expression data. *BMC Bioinformatics* 20 (1), 66, 10.1186/s12859-019-2641-8

86. Nikitin D, Garazha A, Sorokin M, Penzar D, Tkachev V, Markov A, Gaifullin N, Borger P, Poltorak A, **Buzdin A** (2019). Retroelement-Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution. *Cells* 8 (2), 130, 10.3390/cells8020130

87. Zolotovskaia MA, Sorokin MI, Emelianova AA, Borisov NM, Kuzmin DV, Borger P, Garazha AV, **Buzdin AA** (2019). Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. *Front Pharmacol* 10 (JAN), 1, 10.3389/fphar.2019.00001

88. Tkachev V, Sorokin M, Mescheryakov A, Simonov A, Garazha A, **Buzdin A**, Muchnik I, Borisov N (2019). FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier. *Front Genet* 9 (JAN), 717, 10.3389/fgene.2018.00717

89. Rumyantsev PO, Nikiforovich PA, Poloznikov AA, Abrosimov U, Saenko VA, Rogunovich TI, **Budzin AA**, Polyakov AP, Kaprin AD, Dedov II (2019). YSRAEV600E mutation in papillary thyroid carcinoma. Clinical and methodological aspects. *Vopr Onkol* 65 (1), 16–26.

90. Sergeeva AM, Abramova TV, Surin VL, Obukhova TN, Dovydenko MV, Suntsova MV, **Buzdin AA**, Mendeleeva LP (2019). Molecular genetic structure of multiple myeloma tumour cells prior to treatment and at the time of relapse: Short review and case report. *Probl Gematol Pereliv Krovi* 64 (3), 362–374, 10.35754/0234-5730-2019-64-3-362-374

91. **(книга) Buzdin AA**, Borisov NM (2019). MiRImpact as a methodological tool for the analysis of MicroRNA at the level of molecular pathways. *Handbook of Nutrition, Diet, and Epigenetics* 3 (5), 2289–2308, 10.1007/978-3-319-55530-0_91

92. Zolotovskaia MA, Sorokin MI, Roumiantsev SA, Borisov NM, **Buzdin AA** (2019). Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers. *Front Oncol* 8 (JAN), 658, 10.3389/fonc.2018.00658

93. Emelianova AA, Kuzmin DV, Panteleev PV, Sorokin MI, **Buzdin AA**, Ovchinnikova TV (2018). Anticancer Activity of the Goat Antimicrobial Peptide ChMAP-28. *Front Pharmacol* 9, 1501, 10.3389/fphar.2018.01501

94. Shtam T, Naryzhny S, Samsonov R, Karasik D, Mizgirev I, Kopylov A, Petrenko E, Zabrodskaya Y, Kamyshinsky R, Nikitin D, Sorokin M, **Buzdin A**, Gil-Henn H, Malek A (2018). Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling. *Breast Cancer Res Treat* 174 (1), 129–141, 10.1007/s10549-018-5043-0

95. Marggraf MB, Panteleev PV, Emelianova AA, Sorokin MI, Bolosov IA, **Buzdin AA**, Kuzmin DV, Ovchinnikova TV (2018). Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III. *Mar Drugs* 16 (12), , 10.3390/md16120466

96. Shtam T, Naryzhny S, Kopylov A, Petrenko E, Samsonov R, Kamyshinsky R, Zabrodskaya Y, Nikitin D, Sorokin M, **Buzdin A**, Malek A (2018). Functional Properties of Circulating Exosomes Mediated by Surface-Attached Plasma Proteins. *J Hematol (Brossard)* 7 (4), 149–153, 10.14740/jh412w

97. Sorokin M, Kholodenko R, Suntsova M, Malakhova G, Garazha A, Kholodenko I, Poddubskaya E, Lantsov D, Stilidi I, Arhiri P, Osipov A, **Buzdin A** (2018). Oncobox bioinformatical platform for selecting potentially

effective combinations of target cancer drugs using high-throughput gene expression data. *Cancers (Basel)* 10 (10), , 10.3390/cancers10100365

98. **Buzdin A**, Sorokin M, Garazha A, Sekacheva M, Kim E, Zhukov N, Wang Y, Li X, Kar S, Hartmann C, Samii A, Giese A, Borisov N (2018). Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs. *Semin Cancer Biol* 53, 110–124, 10.1016/j.semcancer.2018.06.003

99. Borisov N, Tkachev V, Suntsova M, Kovalchuk O, Zhavoronkov A, Muchnik I, **Buzdin A** (2018). A method of gene expression data transfer from cell lines to cancer patients for machine-learning prediction of drug efficiency. *Cell Cycle* 17 (4), 486–491, 10.1080/15384101.2017.1417706

100. Nikitin D, Penzar D, Garazha A, Sorokin M, Tkachev V, Borisov N, Poltorak A, Prassolov V, **Buzdin AA** (2018). Profiling of human molecular pathways affected by retrotransposons at the level of regulation by transcription factor proteins. *Front Immunol* 9 (JAN), 30, 10.3389/fimmu.2018.00030

101. Sorokin M, Kholodenko R, Grekhova A, Suntsova M, Pustovalova M, Vorobyeva N, Kholodenko I, Malakhova G, Garazha A, Nedoluzhko A, Vasilov R, Poddubskaya E, Kovalchuk O, Adamyan L, Prassolov V, Allina D, Kuzmin D, Ignatev K, Osipov A, **Buzdin A** (2017). Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation. *Oncotarget* 9 (4), 5111–5124, 10.18632/oncotarget.23700

102. Borisov N, Suntsova M, Sorokin M, Garazha A, Kovalchuk O, Aliper A, Ilnitskaya E, Lezhnina K, Korzinkin M, Tkachev V, Saenko V, Saenko Y, Sokov DG, Gaifullin NM, Kashintsev K, Shirokorad V, Shabalina I, Zhavoronkov A, Mishra B, Cantor CR, **Buzdin A** (2017). Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data. *Cell Cycle* 16 (19), 1810–1823, 10.1080/15384101.2017.1361068

103. Larkin B, Ilyukha V, Sorokin M, **Buzdin A**, Vannier E, Poltorak A (2017). Cutting edge: Activation of sting in t cells induces type i IFN responses and cell death. *J Immunol* 199 (2), 397–402, 10.4049/jimmunol.1601999

104. Wirsching A, Melloul E, Lezhnina K, **Buzdin AA**, Ogunshola OO, Borger P, Clavien PA, Lesurtel M (2017). Temporary portal vein embolization is as efficient as permanent portal vein embolization in mice. *Surgery* 162 (1), 68–81, 10.1016/j.surg.2017.01.032

105. **Buzdin AA**, Prassolov V, Garazha AV (2017). Friends-Enemies: Endogenous retroviruses are major transcriptional regulators of human DNA. *Front Chem* 5 (JUN), 35, 10.3389/fchem.2017.00035

106. **(книга)** Aliper AM, Korzinkin MB, Kuzmina NB, Zenin AA, Venkova LS, Smirnov PY, Zhavoronkov AA, **Buzdin AA**, Borisov NM (2017). Mathematical justification of expression-based pathway activation scoring (PAS). *Methods Mol Biol* 1613, 31–51, 10.1007/978-1-4939-7027-83

107. **(книга)** Garazha A, Suntsova M, **Buzdin A** (2017). Structural and functional coevolution of human endogenous retroviruses with our genome. , 479–485, 10.1007/978-3-319-48838-738

108. **(книга) Buzdin AA**, Prassolov V, Zhavoronkov AA, Borisov NM (2017). Bioinformatics meets biomedicine: Oncofinder, a quantitative approach for interrogating molecular pathways using gene expression data. *Methods Mol Biol* 1613, 53–83, 10.1007/978-1-4939-7027-84

109. Petrov I, Suntsova M, Ilnitskaya E, Roumiantsev S, Sorokin M, Garazha A, Spirin P, Lebedev T, Gaifullin N, Larin S, Kovalchuk O, Konovalov D, Prassolov V, Roumiantsev A, **Buzdin A** (2017). Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas. *Oncotarget* 8 (48), 83768–83780, 10.18632/oncotarget.19662

110. **Buzdin AA**, Artcibasova AV, Fedorova NF, Suntsova MV, Garazha AV, Sorokin MI, Allina D, Shalatonin M, Borisov NM, Zhavoronkov AA, Kovalchuk I, Kovalchuk O, Kushch AA (2016). Early stage of cytomegalovirus infection suppresses host microRNA expression regulation in human fibroblasts. *Cell Cycle* 15 (24), 3378–3389, 10.1080/15384101.2016.1241928

111. Aliper A, Belikov AV, Garazha A, Jellen L, Artemov A, Suntsova M, Ivanova A, Venkova L, Borisov N, **Buzdin A**, Mamoshina P, Putin E, Swick AG, Moskalev A, Zhavoronkov A (2016). In search for geroprotectors: In silico screening and in vitro validation of signalome-level mimetics of young healthy state. *Aging (Albany NY)* 8 (9), 2127–2152, 10.18632/aging.101047

112. Alexandrova E, Nassa G, Corleone G, **Buzdin A**, Aliper AM, Terekhanova N, Shepelin D, Zhavoronkov A, Tamm M, Milanesi L, Miglino N, Weisz A, Borger P (2016). Large-scale profiling of signalling pathways reveals an asthma specific signature in bronchial smooth muscle cells. *Oncotarget* 7 (18), 25150–25161,

10.18632/oncotarget.7209

113. Artcibasova AV, Korzinkin MB, Sorokin MI, Shegay PV, Zhavoronkov AA, Gaifullin N, Alekseev BY, Vorobyev NV, Kuzmin DV, Kaprin AD, Borisov NM, **Buzdin AA** (2016). MiRImpact, a new bioinformatic method using complete microRNA expression profiles to assess their overall influence on the activity of intracellular molecular pathways. *Cell Cycle* 15 (5), 689–698, [10.1080/15384101.2016.1147633](10.1080/15384101.2016.1147633)

114. Petrov I, Suntsova M, Mutorova O, Sorokin M, Garazha A, Ilnitskaya E, Spirin P, Larin S, Zhavoronkov A, Kovalchuk O, Prassolov V, Roumiantsev A, **Buzdin A** (2016). Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells. *Aging (Albany NY)* 8 (11), 2936–2947, 10.18632/aging.101102

115. Shepelin D, Korzinkin M, Vanyushina A, Aliper A, Borisov N, Vasilov R, Zhukov N, Sokov D, Prassolov V, Gaifullin N, Zhavoronkov A, Bhullar B, **Buzdin A** (2016). Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human. *Oncotarget* 7 (1), 656–670, 10.18632/ONCOTARGET.6394

116. Lebedev TD, Spirin PV, Suntsova MV, Ivanova AV, **Buzdin AA**, Prokofjeva MM, Rubtsov PM, Prassolov VS (2015). Receptor tyrosine kinase KIT can regulate the expression of genes involved in spontaneous regression of neuroblastoma. *Mol Biol* 49 (6), 943–945, [10.1134/S0026893315060151](10.1134/S0026893315060151)

117. Lebedev TD, Spirin PV, Suntsova MV, Ivanova AV, **Buzdin AA**, Prokofjeva MM, Rubtsov PM, Prassolov VS (2015). Receptor tyrosine kinase KIT may regulate expression of genes involved in spontaneous regression of neuroblastoma. *Mol Biol (Mosk)* 49 (6), 1052–1055, [10.7868/S0026898415060154](10.7868/S0026898415060154)

118. Suntsova M, Garazha A, Ivanova A, Kaminsky D, Zhavoronkov A, **Buzdin A** (2015). Molecular functions of human endogenous retroviruses in health and disease. *Cell Mol Life Sci* 72 (19), 3653–3675, [10.1007/s00018-015-1947-6](10.1007/s00018-015-1947-6)

119. Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, **Buzdin AA**, Zhavoronkov AA, Sidransky D (2015). Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. *Hum Genome Var* 2 (1), 15009, [10.1038/hgv.2015.9](10.1038/hgv.2015.9)

120. Garazha A, Ivanova A, Suntsova M, Malakhova G, Roumiantsev S, Zhavoronkov A, **Buzdin A** (2015). New bioinformatic tool for quick identification of functionally relevant endogenous retroviral inserts in human genome. *Cell Cycle* 14 (9), 1476–1484, [10.1080/15384101.2015.1022696](10.1080/15384101.2015.1022696)

121. Artemov A, Aliper A, Korzinkin M, Lezhnina K, Jellen L, Zhukov N, Roumiantsev S, Gaifullin N, Zhavoronkov A, Borisov N, **Buzdin A** (2015). A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation. *Oncotarget* 6 (30), 29347–29356, 10.18632/oncotarget.5119

122. Venkova L, Aliper A, Suntsova M, Kholodenko R, Shepelin D, Borisov N, Malakhova G, Vasilov R, Roumiantsev S, Zhavoronkov A, **Buzdin A** (2015). Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs. *Oncotarget* 6 (29), 27227–27238, 10.18632/oncotarget.4507

123. Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, **Buzdin AA**, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, Prassolov VS (2014). Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. *Leukemia* 28 (11), 2222–2228, [10.1038/leu.2014.130](10.1038/leu.2014.130)

124. **Buzdin AA**, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS, Smirnov PY, Borisov NM (2014). The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. *Front Mol Biosci* 1 (AUG), 8, 10.3389/fmolb.2014.00008

125. Moskalev AA, Aliper AM, Smit-McBride Z, **Buzdin A**, Zhavoronkov A (2014). Genetics and epigenetics of aging and longevity. *Cell Cycle* 13 (7), 1063–1077, [10.4161/cc.28433](10.4161/cc.28433)

126. Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S, Korzinkin MB, Zhavoronkov AA, **Buzdin AA** (2014). Signaling pathways activation profiles make better markers of cancer than expression of individual genes. *Oncotarget* 5 (20), 10198–10205, 10.18632/oncotarget.2548

127. **Buzdin AA**, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY, Borisov NM (2014). Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. *Front Genet* 5 (MAR), 55, 10.3389/fgene.2014.00055

128. Vishnyakova KS, Babizhayev MA, Aliper AM, **Buzdin AA**, Kudryavzeva AV, Yegorov YE (2014). Stimulation of cell proliferation by carnosine: Cell and transcriptome approaches. *Mol Biol* 48 (5), 718–726,

10.1134/S0026893314050161

129. Aliper AM, Frieden-Korovkina VP, **Buzdin A**, Roumiantsev SA, Zhavoronkov A (2014). A role for G-CSF and GM-CSF in nonmyeloid cancers. *Cancer Med* 3 (4), 737–746, 10.1002/cam4.239

130. Aliper AM, Frieden-Korovkina VP, **Buzdin A**, Roumiantsev SA, Zhavoronkov A (2014). Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer. *Oncotarget* 5 (22), 11345–11353, 10.18632/oncotarget.2489

131. Zhavoronkov A, **Buzdin AA**, Garazha AV, Borisov NM, Moskalev AA (2014). Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. *Front Genet* 5 (MAR), 49, 10.3389/fgene.2014.00049

132. Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, Shegay PV, Sokov DG, Gaifullin NM, Rusakov IG, Aliper AM, Roumiantsev SA, Alekseev BY, Borisov NM, **Buzdin AA** (2014). Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. *Oncotarget* 5 (19), 9022–9032, 10.18632/oncotarget.2493

133. Zabolotneva AA, Zhavoronkov AA, Shegay PV, Gaifullin NM, Alekseev BY, Roumiantsev SA, Garazha AV, Kovalchuk O, Aravin A, **Buzdin AA** (2013). A systematic experimental evaluation of microRNA markers of human bladder cancer. *Front Genet* 4 (NOV), 247, 10.3389/fgene.2013.00247

134. Jones RB, Song H, Xu Y, Garrison KE, **Buzdin AA**, Anwar N, Hunter DV, Mujib S, Mihajlovic V, Martin E, Lee E, Kuciak M, Raposo RAS, Bozorgzad A, Meiklejohn DA, Ndhlovu LC, Nixon DF, Ostrowski MA (2013). LINE-1 retrotransposable element DNA accumulates in HIV-1- infected cells. *J Virol* 87 (24), 13307–13320, 10.1128/JVI.02257-13

135. Suntsova M, Gogvadze EV, Salozhin S, Gaifullin N, Eroshkin F, Dmitriev SE, Martynova N, Kulikov K, Malakhova G, Tukhbatova G, Bolshakov AP, Ghilarov D, Garazha A, Aliper A, Cantor CR, Solokhin Y, Roumiantsev S, Balaban P, Zhavoronkov A, **Buzdin A** (2013). Human-specific endogenous retroviral insert serves as an enhancer for the schizophrenia-linked gene PRODH. *Proc Natl Acad Sci U S A* 110 (48), 19472–19477, 10.1073/pnas.1318172110

136. Zabolotneva AA, Zhavoronkov A, Garazha AV, Roumiantsev SA, **Buzdin AA** (2013). Characteristic patterns of microrna expression in human bladder cancer. *Front Genet* 3 (JAN), 310, 10.3389/fgene.2012.00310

137. Baskaev KK, Kholodenko RV, Malakhova GV, Gaifullin NM, Korzeneva EA, Suntsova MV, **Buzdin AA** (2013). Experimental analysis of human-specific protein-coding open reading frame c11orf72. *Russ. J. Bioorganic Chem.* 39 (2), 131–137, 10.1134/S1068162013020039

138. Alexandrova EA, Olovnikov IA, Malakhova GV, Zabolotneva AA, Suntsova MV, Dmitriev SE, **Buzdin AA** (2012). Sense transcripts originated from an internal part of the human retrotransposon LINE-1 5' UTR. *Gene* 511 (1), 46–53, 10.1016/j.gene.2012.09.026

139. Zabolotneva AA, Bantysh O, Suntsova MV, Efimova N, Malakhova GV, Schumann GG, Gayfullin NM, **Buzdin AA** (2012). Transcriptional regulation of human-specific SVAF1retrotransposons by cis-regulatory MAST2 sequences. *Gene* 505 (1), 128–136, 10.1016/j.gene.2012.05.016

140. Baskaev K, Garazha A, Gaifullin N, Suntsova MV, Zabolotneva AA, **Buzdin AA** (2012). NMETR: Technique for facile recovery of hypomethylation genomic tags. *Gene* 498 (1), 75–80, 10.1016/j.gene.2012.01.097

141. Baskaev KK, **Buzdin AA** (2011). Evolutionarily recent groups of transposable elements in the human genome. *Russian Journal of Genetics: Applied Research* 1 (6), 524–531, 10.1134/S2079059711060049

142. Zabolotneva A, Tkachev V, Filatov F, **Buzdin A** (2010). How many antiviral small interfering RNAs may be encoded by the mammalian genomes? *Biol Direct* 5, 62, 10.1186/1745-6150-5-62

143. Kuzmin D, Gogvadze E, Kholodenko R, Grzela DP, Mityaev M, Vinogradova T, Kopantzev E, Malakhova G, Suntsova M, Sokov D, Ivics Z, **Buzdin A** (2010). Novel strong tissue specific promoter for gene expression in human germ cells. *BMC Biotechnol* 10, 58, 10.1186/1472-6750-10-58

144. Mityaev MV, Kopantzev EP, **Buzdin AA**, Vinogradova TV, Sverdlov ED (2010). Enhancer element potentially involved in human survivin gene promoter regulation in lung cancer cell lines. *Biochemistry (Mosc)* 75 (2), 182–191, 10.1134/S0006297910020082

145. **Buzdin AA** (2010). Functional analysis of retroviral endogenous inserts in the human genome evolution. *Bioorg Khim* 36 (1), 38–46.

146. **Buzdin AA** (2010). A functional analysis of retroviral endogenous inserts in view of human genome evolution. *Russ. J. Bioorganic Chem.* 36 (1), 32–39, 10.1134/S1068162010010048

147. Schumann GG, Gogvadze EV, Osanai-Futahashi M, Kuroki A, Münk C, Fujiwara H, Ivics Z, **Buzdin AA** (2010). Unique functions of repetitive transcriptomes. *Int Rev Cell Mol Biol* 285 (C), 115–188, 10.1016/B978-0-12-381047-2.00003-7

148. Bantysh OB, **Buzdin AA** (2009). Novel family of human transposable elements formed due to fusion of the first exon of gene MAST2 with retrotransposon SVA. *Biochemistry (Mosc)* 74 (12), 1393–1399, 10.1134/S0006297909120153

149. Gogvadze E, Stukacheva E, **Buzdin A**, Sverdlov E (2009). Human-specific modulation of transcriptional activity provided by endogenous retroviral insertions. *J Virol* 83 (12), 6098–6105, 10.1128/JVI.00123-09

150. Ghilarov DA, **Buzdin AA** (2009). Endogenous retroviral sequences control the transcription of many host genes in eukaryotes. , 35–63.

151. Gogvadze E, **Buzdin A** (2009). Retroelements and their impact on genome evolution and functioning. *Cell Mol Life Sci* 66 (23), 3727–3742, 10.1007/s00018-009-0107-2

152. Giliarov DA, Sakharova TA, **Buzdin AA** (2009). [Molecular receptors of taste agents]. *Bioorg Khim* 35 (1), 5–14.

153. Gilyarov DA, Sakharova TA, **Buzdin AA** (2009). Molecular receptors of taste agents. *Russ. J. Bioorganic Chem.* 35 (1), 1–9, 10.1134/S1068162009010014

154. Mityaev MV, Kopantzev EP, **Buzdin AA**, Vinogradova TV, Sverdlov ED (2008). Functional significance of a putative Sp1 transcription factor binding site in the survivin gene promoter. *Biochemistry (Mosc)* 73 (11), 1183–1191, 10.1134/S0006297908110035

155. **Buzdin A** (2007). Human-specific endogenous retroviruses. *ScientificWorldJournal* 7, 1848–1868, 10.1100/tsw.2007.270

156. Gogvadze E, Barbisan C, Lebrun MH, **Buzdin A** (2007). Tripartite chimeric pseudogene from the genome of rice blast fungus Magnaporthe grisea suggests double template jumps during long interspersed nuclear element (LINE) reverse transcription. *BMC Genomics* 8, 360, 10.1186/1471-2164-8-360

157. **Buzdin A**, Gogvadze E, Lebrun MH (2007). Chimeric retrogenes suggest a role for the nucleolus in LINE amplification. *FEBS Lett* 581 (16), 2877–2882, 10.1016/j.febslet.2007.05.034

158. Kholodenko R, Kholodenko I, Sorokin V, Tolmazova A, Sazonova O, **Buzdin A** (2007). Anti-apoptotic effect of retinoic acid on retinal progenitor cells mediated by a protein kinase A-dependent mechanism. *Cell Res* 17 (2), 151–162, 10.1038/sj.cr.7310147

159. **Buzdin AA** (2007). DNA hybridization in solution for mutation detection. , 211–239, 10.1007/978-1-4020-6040-39

160. **Buzdin AA** (2007). Nucleic acids hybridization: Potentials and limitationS. , 1–28, 10.1007/978-1-4020-6040-31

161. **Buzdin AA**, Lukyanov SA (2007). Stem-loop oligonucleotides as hybridization probes and their practical use in molecular biology and biomedicine. , 85–96, 10.1007/978-1-4020-6040-34

162. Lukyanov SA, Lukyanov KA, Gurskaya NG, Bogdanova EA, **Buzdin AA** (2007). Selective suppression of polymerase chain reaction and its most popular applications. , 29–51, 10.1007/978-1-4020-6040-32

163. **Buzdin AA** (2007). Current attempts to improve the specificity of nucleic acids hybridization. , 241–264, 10.1007/978-1-4020-6040-310

164. **Buzdin AA** (2007). Coincidence cloning: Robust technique for isolation of common sequences. , 187–210, 10.1007/978-1-4020-6040-38

165. Lukyanov SA, Rebrikov D, **Buzdin AA** (2007). Suppression subtractive hybridization. , 53–84, 10.1007/978-1-4020-6040-33

166. **Buzdin A**, Kovalskaya-Alexandrova E, Gogvadze E, Sverdlov E (2006). At least 50% of human-specific HERV-K (HML-2) long terminal repeats serve in vivo as active promoters for host nonrepetitive DNA transcription. *J Virol* 80 (21), 10752–10762, 10.1128/JVI.00871-06

167. **Buzdin A**, Kovalskaya-Alexandrova E, Gogvadze E, Sverdlov E (2006). GREM, a technique for genome-wide isolation and quantitative analysis of promoter active repeats. *Nucleic Acids Res* 34 (9), e67, 10.1093/nar/gkl335

168. Kholodenko IV, **Buzdin AA**, Kholodenko RV, Baibikova JA, Sorokin VF, Yarygin VN, Sverdlov ED (2006). Mouse retinal progenitor cell (RPC) cocultivation with retinal pigment epithelial cell culture affects features of RPC differentiation. *Biochemistry (Mosc)* 71 (7), 767–774, 10.1134/S0006297906070091

169. Kovalskaya E, **Buzdin A**, Gogvadze E, Vinogradova T, Sverdlov E (2006). Functional human endogenous retroviral LTR transcription start sites are located between the R and U5 regions. *Virology* 346 (2), 373–378, 10.1016/j.virol.2005.11.007

170. **Buzdin A** (2006). Transposable elements and their use for target site specific gene delivery. *Current Pharmacogenomics* 4 (1), 1–8, 10.2174/157016006776055437

171. Gogvadze EV, **Buzdin AA** (2005). New mechanism of retrogene formation in mammalian genomes: In vivo Recombination during RNA reverse transcription. *Mol Biol (Mosk)* 39 (3), 364–373.

172. **Buzdin A**, Vinogradova T, Lebedev Y, Sverdlov E (2005). Genome-wide experimental identification and functional analysis of human specific retroelements. *Cytogenet Genome Res* 110 (14), 468–474, 10.1159/000084980

173. Gogvadze EV, **Buzdin AA** (2005). A new mechanism of retrogene formation in mammalian genomes: In vivo recombination during RNA reverse transcription. *Mol Biol* 39 (3), 321–330, 10.1007/s11008-005-0045-5

174. Gogvadze EV, **Buzdin AA**, Sverdlov ED (2005). Multiple template switches on LINE-directed reverse transcription: the most probable formation mechanism for the double and triple chimeric retroelements in mammals. *Bioorg Khim* 31 (1), 82–89.

175. Gogvadze EV, **Buzdin AA**, Sverdlov ED (2005). Multiple template switches on LINE-directed reverse transcription: The most probable formation mechanism for the double and triple chimeric retroelements in mammals. *Russ. J. Bioorganic Chem.* 31 (1), 74–81, 10.1007/s11171-005-0010-z

176. **Buzdin AA** (2004). Retroelements and formation of chimeric retrogenes. *Cell Mol Life Sci* 61 (16), 2046–2059, 10.1007/s00018-004-4041-z

177. Chalaya T, Gogvadze E, **Buzdin A**, Kovalskaya E, Sverdlov ED (2004). Improving specificity of DNA hybridization-based methods. *Nucleic Acids Res* 32 (16), e130, 10.1093/nar/gnh125

178. **Buzdin A**, Gogvadze E, Kovalskaya E, Volchkov P, Ustyugova S, Illarionova A, Fushan A, Vinogradova T, Sverdlov E (2003). The human genome contains many types of chimeric retrogenes generated through in vivo RNA recombination. *Nucleic Acids Res* 31 (15), 4385–4390, 10.1093/nar/gkg496

179. **Buzdin A**, Ustyugova S, Gogvadze E, Lebedev Y, Hunsmann G, Sverdlov E (2003). Genome-wide targeted search for human specific and polymorphic L1 integrations. *Hum Genet* 112 (56), 527–533, 10.1007/s00439-002-0904-2

180. **Buzdin A**, Ustyugova S, Khodosevich K, Mamedov I, Lebedev Y, Hunsmann G, Sverdlov E (2003). Human-specific subfamilies of HERV-K (HML-2) long terminal repeats: Three master genes were active simultaneously during branching of hominoid lineages. *Genomics* 81 (2), 149–156, 10.1016/S0888-7543(02)00027-7

181. **Buzdin AA**, Lebedev YB, Sverdlov ED (2003). Human-Specific HERV-K Intron LTRs Have Nonaccidental Opposite Orientation Relative to the Direction of Gene Transcription and Might Be Involved in the Antisense Regulation of Gene Expression. *Russ. J. Bioorganic Chem.* 29 (1), 91–93, 10.1023/A:1022294906202

182. **Buzdin AA**, Lebedev IB, Sverdlov ED (2003). Human genome-specific HERV-K intron LTR genes have a random orientation relative to the direction of transcription, and, possibly, participated in antisense gene expression regulation. *Bioorg Khim* 29 (1), 103–106.

183. Mamedov I, Batrak A, **Buzdin A**, Arzumanyan E, Lebedev Y, Sverdlov ED (2002). Genome-wide comparison of differences in the integration sites of interspersed repeats between closely related genomes. *Nucleic Acids Res* 30 (14), e71, 10.1093/nar/gnf071

184. **Buzdin A**, Ustyugova S, Gogvadze E, Vinogradova T, Lebedev Y, Sverdlov E (2002). A new family of chimeric retrotranscripts formed by a full copy of U6 small nuclear RNA fused to the 3′ terminus of L1. *Genomics* 80 (4), 402–406, 10.1006/geno.2002.6843

185. **Buzdin A**, Khodosevich K, Mamedov I, Vinogradova T, Lebedev Y, Hunsmann G, Sverdlov E (2002). A technique for genome-wide identification of differences in the interspersed repeats integrations between closely related genomes and its application to detection of human-specific integrations of HERV-K LTRs. *Genomics* 79 (3), 413–422, 10.1006/geno.2002.6705

186. Krieger IV, Revina LP, Kostina LI, **Buzdin AA**, Zalunin IA, Chestukhina GG, Stepanov VM (1999). Membrane Proteins of Aedes aegypti Larvae Bind Toxins Cry4B and Cry11A of Bacillus thuringiensis ssp. israelensis. *Biochemistry (Mosc)* 64 (10), 1163–1168.